<DOC>
	<DOCNO>NCT02662309</DOCNO>
	<brief_summary>ABACUS open-label , international , multi-centre , window opportunity phase II trial patient histologically confirm ( T2-T4a ) transitional cell carcinoma bladder . The trial aim test efficacy preoperative MPDL3280A include extensive biomarker work sample patient . Eligible patient receive two 3-weekly cycle MPDL3280A pre-cystectomy . Following cystectomy , patient follow safety , survival , disease data .</brief_summary>
	<brief_title>Preoperative MPDL3280A Transitional Cell Carcinoma Bladder</brief_title>
	<detailed_description>MPDL3280A ( also call atezolizumab ) immune check point inhibitor target program death-ligand 1 ( PD-L1 ) . Overexpression PD-L1 prevents immune system eradicate cancerous cell block antigen recognition . MPDL3280A inhibit interaction , allow immune-mediated tumour cell kill .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Willing able provide write informed consent 2 . Ability comply protocol 3 . Age ≥ 18 year 4 . Histopathologically confirm transitional cell carcinoma ( T2T4a ) bladder . Patients mixed histology require dominant transitional cell pattern . 5 . Residual disease TURBT ( surgical opinion , cystoscopy radiological presence ) . 6 . Fit plan cystectomy ( accord local guideline ) . 7 . N0 M0 disease CT MRI ( within 4 week registration ) 8 . Representative formalinfixed paraffin embed ( FFPE ) bladder tumour sample associate pathology report determine available sufficient central test . 9 . Patients refuse neoadjuvant cisplatin base chemotherapy neoadjuvant cisplatin base therapy appropriate . 10 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 11 . Negative pregnancy test within 2 week Day 1 Cycle 1 female patient childbearing potential . 12 . For female patient childbearing potential use highly effect form ( ) contraception ( i.e . one result low failure rate [ &lt; 1 % per year ] use consistently correctly ) continue use 90 day last dose MPDL3280A . 13 . Adequate hematologic endorgan function within 4 week prior first study treatment define follow : ANC ≥ 1500 cells/μL ( without granulocyte colonystimulating factor support within 2 week prior Cycle 1 , Day 1 ) WBC count &gt; 2500/μL Lymphocyte count ≥ 500/μL Platelet count ≥ 100,000/μL ( without transfusion within 2 week prior Cycle 1 , Day 1 ) Haemoglobin ≥ 9.0 g/dL ( patient may transfuse receive erythropoietic treatment meet criterion ) . AST ALT , alkaline phosphatase ≤ 2.5 time institutional upper limit normal ( ULN ) ( patient know Gilbert disease serum bilirubin level ≤ 3 × institutional ULN may enrol ) . INR aPTT ≤ 1.5 × institutional ULN . This apply patient receive therapeutic anticoagulation ; patient receive therapeutic anticoagulation stable dose . Calculated creatinine clearance ≥ 20 mL/min ( CockcroftGault formula ) 1 . Pregnant lactate female patient . 2 . Major surgical procedure within 4 week prior enrolment anticipation need major surgical procedure course study diagnosis . 3 . Previously intravenous chemotherapy bladder cancer . 4 . Patients prior allogeneic stem cell solid organ transplantation . 5 . Prior treatment CD137 agonist , antiCTLA4 , anti−programmed death−1 ( PD1 ) , anti−PDL1 therapeutic antibody pathwaytargeting agent . 6 . Patients must oral IV steroid 14 day prior study entry . The use inhaled corticosteroid , physiologic replacement dos glucocorticoid ( i.e. , adrenal insufficiency ) , mineralocorticoid ( e.g. , fludrocortisone ) allow . 7 . Received therapeutic oral intravenous ( IV ) antibiotic within 14 day prior enrolment ( Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection chronic obstructive pulmonary disease ) eligible ) . 8 . Administration live , attenuated vaccine within 4 week prior enrolment anticipation live , attenuated vaccine require study . 9 . Treatment systemic immunostimulatory agent ( include limit interferon interleukin [ IL ] −2 ) within 4 week five halflives drug , whichever short , prior enrolment . 10 . Treatment investigational agent participation another clinical trial therapeutic intent within 4 week prior enrolment . 11 . Evidence significant uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant liver disease ( cirrhosis , uncontrolled major seizure disorder , superior vena cava syndrome ) . 12 . Malignancies UBC within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death treat expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , ductal carcinoma situ treat surgically curative intent ) localize prostate cancer treat curative intent absence prostatespecific antigen ( PSA ) relapse incidental prostate cancer ( Gleason score ≤ 3 + 4 PSA &lt; 10 ng/mL undergo active surveillance treatment naive ) . 13 . Severe infection within 4 week prior enrolment study include limited hospitalization complication infection , bacteraemia , severe pneumonia . 14 . Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction within 3 month prior enrolment , unstable arrhythmia , unstable angina . 15 . History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia ) , evidence active pneumonitis screen chest CT scan ( History radiation pneumonitis radiation field ( fibrosis ) permit ) . 16 . Patients uncontrolled Type 1 diabetes mellitus . Patients Type 1 diabetes control stable insulin regimen eligible . 17 . Patients active hepatitis infection ( define positive hepatitis B surface antigen [ HBsAg ] test screening ) hepatitis C. Patients past hepatitis B virus ( HBV ) infection resolve HBV infection ( define negative HBsAg test positive antibody hepatitis B core antigen [ antiHBc ] antibody test ) eligible . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV RNA . 18 . Positive test HIV 19 . Patients active tuberculosis 20 . History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug . 21 . Uncontrolled hypercalcemia ( &gt; 1.5 mmol/L ionize calcium Ca &gt; 12 mg/dL correct serum calcium &gt; institutional ULN ) symptomatic hypercalcemia require continue use bisphosphonate therapy denosumab . Patients receive bisphosphonate therapy denosumab specifically prevent skeletal event history clinically significant hypercalcemia eligible . Patients receive denosumab prior enrollment must willing eligible receive bisphosphonate instead study . 22 . History autoimmune disease include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis . 23 . Patients history autoimmunerelated hypothyroidism , unless stable dose thyroidreplacement hormone . 24 . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins 25 . Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component MPDL3280A formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Muscle invasive bladder cancer</keyword>
	<keyword>Transitional cell carcinoma</keyword>
</DOC>